NCT00259155View on ClinicalTrials.gov

Rifaximin for the Treatment of Irritable Bowel Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Rifaximin

All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT00259155 - Rifaximin for the Treatment of Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter